RVMD Stock Overview A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Revolution Medicines, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Revolution Medicines Historical stock prices Current Share Price US$44.39 52 Week High US$62.40 52 Week Low US$25.93 Beta 1.4 1 Month Change -24.29% 3 Month Change 0.50% 1 Year Change 51.14% 3 Year Change 73.47% 5 Year Change n/a Change since IPO 53.60%
Recent News & Updates
CEO, President & Chairman notifies of intention to sell stock Dec 18 Revolution Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $750.000021 million. Dec 05
Revolution Medicines: Risky Buy On Recent Share Price Dip Dec 04 Revolution Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $750.000021 million. Dec 04
Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $600 million. Dec 03
Revolution Medicines, Inc. Provides Clinical Updates from Its RAS(ON) Inhibitor Portfolio Dec 02 See more updates
CEO, President & Chairman notifies of intention to sell stock Dec 18 Revolution Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $750.000021 million. Dec 05
Revolution Medicines: Risky Buy On Recent Share Price Dip Dec 04 Revolution Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $750.000021 million. Dec 04
Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $600 million. Dec 03
Revolution Medicines, Inc. Provides Clinical Updates from Its RAS(ON) Inhibitor Portfolio Dec 02
President of Research & Development exercised options and sold US$909k worth of stock Nov 18
CEO, President & Chairman exercised options and sold US$3.1m worth of stock Nov 11
CEO, President & Chairman recently sold US$550k worth of stock Nov 07
Consensus revenue estimates decrease by 57% Nov 05
CEO, President & Chairman notifies of intention to sell stock Nov 04
Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
Chief Operating Officer notifies of intention to sell stock Oct 15
CEO, President & Chairman notifies of intention to sell stock Oct 03
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD) Sep 28
President of Research & Development notifies of intention to sell stock Sep 16
President of Research & Development notifies of intention to sell stock Aug 15
Consensus revenue estimates fall by 76% Aug 14
First half 2024 earnings released: US$1.51 loss per share (vs US$1.64 loss in 1H 2023) Aug 08 Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.
CEO, President & Chairman notifies of intention to sell stock Aug 04
Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Jul 16
CEO, President & Chairman notifies of intention to sell stock Jul 15
Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer Jul 12
Now 31% overvalued after recent price rise Jul 09
CEO, President & Chairman notifies of intention to sell stock Jun 17
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate Jun 15
Revolution Medicines: On Hold Pending A Lower Entry Point Jun 04
Consensus revenue estimates decrease by 52%, EPS upgraded May 15
Price target increased by 7.8% to US$44.82 May 12
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 10
First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023) May 09
Chief Financial Officer notifies of intention to sell stock May 06
Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
Price target increased by 7.1% to US$41.58 Apr 19
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity Apr 12
Price target increased by 7.7% to US$39.83 Apr 11
Chief Operating Officer notifies of intention to sell stock Mar 13 Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million. Mar 05
Consensus revenue estimates fall by 92% Mar 04
Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024 Feb 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 27
New major risk - Revenue and earnings growth Feb 23
Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 21
Revolution Medicines Is Hard To Understand Feb 01
President of Research & Development notifies of intention to sell stock Dec 30
New major risk - Shareholder dilution Nov 14
Price target decreased by 7.0% to US$34.14 Nov 13
Consensus revenue estimates decrease by 31% Nov 13
Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Nov 11 Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Nov 10
Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022) Nov 07
Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Nov 01
Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 Oct 24
New major risk - Revenue and earnings growth Oct 23
Price target increased by 7.9% to US$37.14 Oct 23 Revolution Medicines, Inc. Provides Pipeline Updates
New minor risk - Share price stability Oct 14
President of Research & Development notifies of intention to sell stock Oct 13
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Sep 20
Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors Sep 08
CEO, President & Chairman notifies of intention to sell stock Sep 03
Consensus revenue estimates increase by 15%, EPS downgraded Aug 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023 Aug 09
Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 04
President of Research & Development notifies of intention to sell stock Aug 03
Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Aug 03
Price target increased by 9.4% to US$34.29 Aug 02 Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index
Consensus revenue estimates decrease by 25% May 15
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10 Revolution Medicines, Inc. Announces Executives Appointment
Consensus revenue estimates fall by 34% Mar 06
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 01
Price target increased by 9.0% to US$32.22 Feb 28
Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552 Dec 20
Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration Dec 09
Revolution Medicines, Inc. Updates Earnings Guidance for 2022 Dec 08
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 09
Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 08 Shareholder Returns RVMD US Biotechs US Market 7D 2.5% 2.1% 2.8% 1Y 51.1% -3.8% 24.5%
See full shareholder returns
Return vs Market: RVMD exceeded the US Market which returned 24.8% over the past year.
Price Volatility Is RVMD's price volatile compared to industry and market? RVMD volatility RVMD Average Weekly Movement 6.4% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Stable Share Price: RVMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RVMD's weekly volatility (6%) has been stable over the past year.
About the Company Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
Show more Revolution Medicines, Inc. Fundamentals Summary How do Revolution Medicines's earnings and revenue compare to its market cap? RVMD fundamental statistics Market cap US$7.47b Earnings (TTM ) -US$567.06m Revenue (TTM ) US$742.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RVMD income statement (TTM ) Revenue US$742.00k Cost of Revenue US$426.14m Gross Profit -US$425.40m Other Expenses US$141.66m Earnings -US$567.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.37 Gross Margin -57,331.27% Net Profit Margin -76,423.32% Debt/Equity Ratio 0%
How did RVMD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 00:55 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Revolution Medicines, Inc. is covered by 17 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Alec Stranahan BofA Global Research Chris Shibutani Goldman Sachs
Show 14 more analysts 
